Supporting HIV care through education and innovation

Buprenorphine Training Manual Notes

Buprenorphine Training Manual Notes

August 2012
Author:
IHIP
HRSA HIV/AIDS Bureau
  1. Egan JE, Netherland J, Gass J. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. JAIDS. 2011;56(Suppl 4):S48.
  2. Friedland G, Vlahov D. Integration of buprenorphine for substance-abuse treatment by HIV care providers. JAIDS. 2011;56(Suppl 1):S1–S2.
  3. U.S. Centers for Disease Control and Prevention (CDC). HIV Surveillance Report. 2010.(22). Table 2b.
  4. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. JAIDS. 2011;56 (Suppl 1):S22–32.
  5. Substance Abuse and Mental Health Services Administration (SAMHSA). 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings). Rockville, MD.
  6. Harvard Medical School. Treating opiate addiction, part 1: detoxification and maintenance. Harvard Medical School Family Health Guide, 2005. Accessed December 16, 2011.
  7. SAMHSA. 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings). Rockville, MD.
  8. Lum P, Little S, Botsko M, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. JAIDS. 2011;56(Suppl 4):S91–7.
  9. Lum P, Tulsky JP. The medical management of opioid dependence in HIV primary care settings. Current HIV/AIDS Reports. 2006;3(4):185–94.
  10. Cheever LW, Kresina TF, Cajina A, et al. A model Federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. JAIDS. 2011;56(Suppl 1):S3–S6.
  11. Tsao JC, Dobalian A, Naliboff BD. Panic disorder and pain in a national sample of persons living with HIV. Pain. 2004;109(1-2):172–80.
  12. Rosenfeld B, Breitbart W, McDonald MV, et al. Pain in ambulatory AIDS patients. II: impact of pain on psychological functioning and quality of life. Pain. 1996;68(2-3):323–8.
  13. Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage. 1999;18(4):253–62.
  14. Del Borgo C, Izzi I, Chiarotti F, et al. Multidimensional aspects of pain in HIV-infected individuals. AIDS Patient Care STDS. 2001;15(2):95–102.
  15. Tsao JC, Stein JA, Dobalian A. Pain, problem drug use history, and aberrant analgesic use behaviors in persons living with HIV. Pain. 2007;133(1-3):128–37.
  16. Health Resources and Services Administration (HRSA), Special Projects of National Significance (SPNS). An evaluation of innovative methods for integrating buprenorphine opioid abuse treatment in HIV primary care settings: demonstration models and evaluation and support. Program guidance. 2004.
  17. Hanson T, Alessi SM, Petry NM. Contingency management reduces drug-drug human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients. Addiction. 2008;103(7):1187–97.
  18. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care Psychological and Socio-Medical Aspects of AIDS/HIV. 2004;16(2):199–211.
  19. Berg KM, Demas PA, Howard AA, et al. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111–17.
  20. Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.
  21. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.
  22. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. JAIDS. 2006;43(4):411–381.
  23. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005;29(7):1190–97.
  24. Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health. 2003;80(4):667–75.
  25. Conigliaro J, Gordon AJ, McGinnis KA, et al. How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? JAIDS. 2003;33(4):521–25.
  26. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.
  27. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–43.
  28. Wood E, Kerr T, Zhang R, et al. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. HIV Med. 2008;9(7):503–7.
  29. Shannon K, Kerr T, Lai C, et al. Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care. 2005;4(3):66–72.
  30. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.
  31. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5-6):347–64.
  32. Stancliff S, Myers JE, Steiner S, et al. Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002;79(4):571–78.
  33. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93(4):515–32.
  34. Weiss L, Egan JE, Botsko M, et al. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. JAIDS. 2011;56(1):S7–S13.
  35. HRSA. Buprenorphine: making opioid treatment a primary concern. What’s Going on @ SPNS bulletin. March 2008.
  36. HRSA. Medication-assisted addiction therapy. May 2011. HRSA CARE Action. Accessed December 11, 2011.
  37. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. Fourth edition, text revision. Washington, DC: American Psychiatric Association, 2000.
  38. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006;43(Suppl 4):S173–77.
  39. Kerr T, Marshall A, Walsh J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5):539–49.
  40. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS. 2005;19:326–34
  41. Cheever LW, Kresina TF, Cajina A, et al. A model Federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. JAIDS. 2011;56(Suppl 1):S3.
  42. Basu S, Smith-Rohrberg D, Bruce RD, et al. Models for integrating buprenorphine therapy into the primary HIV care settings. Clin Infect Dis. 2006;42(5):716–21.
  43. Finkelstein R. New York Academy of Medicine. Integration of HIV care & substance abuse treatment. [Conference presentation.] Ryan White All-Grantee Meeting, Washington, DC. August 2008.
  44. Korthuis PT, Fiellin DA, Rongwei F, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. JAIDS. 2011;43(Suppl 4):S83–90.
  45. Warden J, Hunter C, Miller V [Ed.] Forum for Collaborative HIV Research. Buprenorphine and Primary HIV Care: report of a forum for Collaborative HIV Research workshop. June 3–4, 2004. Washington, DC. Accessed December 21, 2011.
  46. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006;43(Suppl 4):S191–96.
  47. HRSA, SPNS. An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care. n.d. Accessed December 11, 2011.
  48. Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid-dependent patient receiving buprenorphine/naloxone. JAIDS. 2011;56(Suppl 1):S33–34.
  49. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international experience. CID; 2006;43(Suppl 4):S207.
  50. Fiellin DA, O’Connor PG. Clinical practice. Officebased treatment of opioid-dependent patients. N Engl J Med. 2002;347:817–23.
  51. Reckitt Benckiser. Discontinuation of sale and distribution of Subutex tablets CIII. September 16, 2011. Accessed December 11, 2011.
  52. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international experience. CID; 2006;43(Suppl 4):S197–215.
  53. SAMHSA. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol (TIP) 40. Accessed December 11, 2011.
  54. HRSA. Buprenorphine: a new tool in the arsenal. March 2004. HRSA CAREAction.
  55. Fudala PJ, Bridge P, Herbert S. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.
  56. Clark HW. Office-based practices and opioid-use disorder. N Engl J. Med. 2003;349(10):928–31.
  57. U.S. Food and Drug Administration (FDA). Physician information: answers to frequently asked questions. n.d. Accessed December 11, 2011.
  58. FDA. Personal communication, December 7, 2011.
  59. National Alliance of Advocates for Buprenorphine Treatment (NAABT). Is buprenorphine addictive? n.d. Accessed December 16, 2011.
  60. SAMHSA. Personal communication, November 30, 2011.
  61. Raisch DW, Fye CL, Boardman KD, et al. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002;36(2):312–21.
  62. SAMHSA. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol (TIP) 40. Page 7. Accessed December 11, 2011.
  63. New York State Office of Alcoholism and Substance Abuse Services. Buprenorphine. January 2008. Accessed December 21, 2011.
  64. Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid-dependent patient receiving buprenorphine/naloxone. JAIDS. 2011;56(Suppl 1):S33–38.
  65. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–8.
  66. HRSA. Addressing comorbidities: the hepatitis C treatment expansion initiative. What’s Going on @ SPNSAugust 2011. Accessed December 22, 2011.
  67. Healthwise. London WT, Romito K [Eds.] Liver function tests. WebMD. 2009. Accessed December 22, 2011.
  68. Martin AJ. New national study finds buprenorphine reduces heroin use. The New York Academy of Medicine. March 7, 2011. Accessed October 25, 2011.
  69. HRSA, SPNS. Integrating buprenorphine therapy into HIV primary care settings. April 2012.
  70. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770–8.
  71. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628–3.
  72. Roux P, Carrieri MP, Villes V, et al; MANIF2000 cohort study group. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008;103(11):1828–36.
  73. Simoens S, Matheson C, Bond C, et al. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55(511):139–46.
  74. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. JAIDS. 2011;56(Suppl 1):S27.
  75. Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152(11):704–11.
  76. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. JAIDS. 2011;56(Suppl 1):S30.
  77. SAMHSA. Buprenorphine: how to obtain a waiver. n.d. Accessed December 9, 2011.
  78. HRSA, SPNS. Integrating buprenorphine therapy into HIV primary care settings. April 2012, p.47.
  79. SAMSHA. Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies; 2009.
  80. SAMHSA. Buprenorphine: physician waiver qualifications. n.d. Accessed October 25, 2011.
  81. Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81(9):1185–91.
  82. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991.
  83. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–9.
  84. Legal Action Center. Confidentiality: a guide to the Federal laws and regulations. New York, NY: Legal Action Center, 1991.
  85. Schackman BR, Merrill JO, McCarthy D, et al. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Suppl 4):S247–53.
  86. Schackman BR, Merrill JO, McCarthy D, et al. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Suppl 4):S248.
  87. SAMHSA. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol, TIP 40. Page 84. 2010. Accessed December 16, 2011.
  88. Salsitz E, Wunsch MJ. New York State Office of Alcoholism and Substance Abuse Services. DEA requirements for prescribers and dispensers of buprenorphine and buprenorphine/naloxone. ASAM physician clinical support system guidance. December 31, 2009.
  89. NAABT. What is precipitated withdrawal? 2008. Accessed December 16, 2011.
  90. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253–9.
  91. HIV/AIDS Bureau, SPNS. Integrating buprenorphine therapy into HIV primary care settings. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration; 2012.
  92. NAABT. What is precipitated withdrawal? n.d. Accessed October 25, 2011.
  93. Kaminski DM. AIDS Community Research Initiative of America. Buprenorphine: the new kid on the block. ACRIA Update. 2005;14(2):22.
  94. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18(7):853–61.
  95. McLennan AT, Luborsky L, Caccioa J, et al. New data from the addiction severity index: reliability and validity in three centers. J Nerv Ment Dis. 1985;173(7):412–23.
  96. Wu AW, Hays RD, Kelly S, et al. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/ AIDS. Qual Life Res. 1997;6(6):531–54.
  97. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171–78.
  98. Radloff LS. The CES-D scale: a self-report depression scale for research in the general public. Appl Psychol Meas. 1977;1(3):385–401.
  99. Sullivan LE, Moore BA, O’Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict. 2010;19(1):53–58.
  100. HRSA, SPNS. Integrating buprenorphine therapy into HIV primary care settings. April 2012, p.94.
  101. HRSA, SPNS. Integrating buprenorphine therapy into HIV primary care settings. April 2012, p.95.
  102. Schackman BR, Leff JA, Botsko M, et al. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. JAIDS. 2011;56(1):S76–82.
  103. HRSA, SPNS. Integrating buprenorphine therapy into HIV primary care settings. April 2012, p.25.
  104. Weiss L, Netherland J, Egan JE. Integration of buprenorphine/ naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. JAIDS. 2011;56(Suppl 1):S68–75.

Add a Comment

Log in or register to post comments